The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual <scp>GLP</scp> ‐1/ <scp>GIP</scp> receptor agonist ( <scp>BGM0504</scp> ) in healthy volunteers: A dose‐escalation Phase I study
BGM0504 was generally safe and well tolerated with favourable PK profile and potential role in weight loss was also confirmed. These findings support subsequent development of BGM0504 for type 2 diabetes mellitus (T2DM) and obesity.
Authors
- Daosheng Xie
- Jiandong Yuan (ORCID: https://orcid.org/0009-0002-9281-4433)
- Weibo Wen (ORCID: https://orcid.org/0000-0003-3404-2738)
- Jenny Ling‐Yu Chen (ORCID: https://orcid.org/0000-0001-8553-8069)
- Ruixia Li (ORCID: https://orcid.org/0000-0002-9620-9145)
- Haifeng Ding (ORCID: https://orcid.org/0000-0001-7524-0779)
- Jianchang He (ORCID: https://orcid.org/0000-0002-4062-2037)
- Yuxin Fan (ORCID: https://orcid.org/0000-0003-1561-1472)
- Mei Yang (ORCID: https://orcid.org/0000-0002-0423-6358)
- Runfang Guan
- Shuxian Long
- Yü Huang (ORCID: https://orcid.org/0000-0002-1277-6784)
- Chongjing Yu
- Wenhong Zou
Institutions
- Kunming University of Science and Technology (CN)
- Yunnan University (CN)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1111/dom.16203
- Citations
- 4
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 5.18
Funders
- Yunnan Provincial Science and Technology Department